I've said it as have you I don't think the market will give a monkeys when it's re-released and surely the current price has nothing in it for Affidx.
It has proved in a lateral flow application affimers are as good if not better than antibodies though which is good for Avacta. Would have been even better if they only used affimers obviously.
I think the only option in the UK is workplace but even then very limited. If all restrictions are lifted in England (which they are about to be) and there is no legal requirements to isolate why would anyone bother paying for a test if they felt a bit rough?
More about future use of lfts now and what the dx division can come up with for the future
Not a lot to discuss really , until the data is out from ava6k. Other than the twats telling us how much we've dropped and how much more we'll drop, that's about it....